Barclays’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-259,160
| Closed | -$881K | – | 7692 |
|
|
2018
Q3 | $881K | Buy |
259,160
+192,403
| +288% | +$694K | ﹤0.01% | 3750 |
|
|
2018
Q2 | $252K | Buy |
66,757
+23,616
| +55% | +$115K | ﹤0.01% | 4531 |
|
|
2018
Q1 | $176K | Sell |
43,141
-44,913
| -51% | -$209K | ﹤0.01% | 4949 |
|
|
2017
Q4 | $409K | Sell |
88,054
-48,561
| -36% | -$268K | ﹤0.01% | 4052 |
|
|
2017
Q3 | $970K | Buy |
136,615
+66,371
| +94% | +$477K | ﹤0.01% | 3029 |
|
|
2017
Q2 | $507K | Buy |
70,244
+43,795
| +166% | +$274K | ﹤0.01% | 3515 |
|
|
2017
Q1 | $164K | Buy |
26,449
+19,799
| +298% | +$108K | ﹤0.01% | 4500 |
|
|
2016
Q4 | $40K | Sell |
6,650
-34,904
| -84% | -$191K | ﹤0.01% | 5306 |
|
|
2016
Q3 | $221K | Buy |
41,554
+2,717
| +7% | +$14.7K | ﹤0.01% | 3894 |
|
|
2016
Q2 | $258K | Buy |
38,837
+18,656
| +92% | +$104K | ﹤0.01% | 3736 |
|
|
2016
Q1 | $81K | Buy |
20,181
+18,957
| +1,549% | +$75.7K | ﹤0.01% | 4504 |
|
|
2015
Q4 | $6K | Sell |
1,224
-24,413
| -95% | -$116K | ﹤0.01% | 5545 |
|
|
2015
Q3 | $78K | Buy |
25,637
+1,049
| +4% | +$7.03K | ﹤0.01% | 4774 |
|
|
2015
Q2 | $222K | Sell |
24,588
-2,217
| -8% | -$23.8K | ﹤0.01% | 4077 |
|
|
2015
Q1 | $322K | Buy |
26,805
+4,101
| +18% | +$52.7K | ﹤0.01% | 3980 |
|
|
2014
Q4 | $317K | Buy |
22,704
+6,848
| +43% | +$106K | ﹤0.01% | 4261 |
|
|
2014
Q3 | $206K | Buy |
15,856
+3,131
| +25% | +$47.9K | ﹤0.01% | 4727 |
|
|
2014
Q2 | $189K | Buy |
12,725
+1,744
| +16% | +$24.7K | ﹤0.01% | 4875 |
|
|
2014
Q1 | $187K | Sell |
10,981
-37,128
| -77% | -$560K | ﹤0.01% | 4856 |
|
|
2013
Q4 | $578K | Sell |
48,109
-41,245
| -46% | -$493K | ﹤0.01% | 3953 |
|
|
2013
Q3 | $893K | Buy |
89,354
+36,947
| +71% | +$329K | ﹤0.01% | 3478 |
|
|
2013
Q2 | $392K | Buy |
+52,407
| New | +$410K | ﹤0.01% | 4494 |
|
Barclays's KERX Position: Q4 2018 in Review
Barclays sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 259,160 shares — an estimated $881K sold.
Barclays first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $970K in Q3 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Barclays reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Barclays sold 259,160 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $881K.
- Barclays first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Barclays's Keryx Biopharmaceuticals Inc position peaked at $970K in Q3 2017.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Barclays's 13F filing for Q4 2018, filed 14 Feb 2019.